Gapping up
In reaction to strong earnings/guidance:
- MX +17%, MEDP +16.8%, IVAC +12.2%, CGNX +8%, CHGG +7.9%, IGT +7.6%, ILMN +7.2%, SPWR +6.8%, SSD +5.8%, RRC +4.7%, SANM +4.6%, RBBN +4.6%, KLAC +4.2%, PAGS +4.1%, ALSN +4%, ADM +3.6%, HUN +3.3%, OSK +3.3%, CS +3.2%, CMI +2.8%, APPF +2.6%, SNE +2.6%, BTE +2.2%, IDTI +1.8%, XYL +1.7%, BP +1.6%, HMC +1.6%, INCY +1.6%, SHOP +1.2%, TNET +1.1%, VNTR +1.1%, ETN +1%, RIG +0.9%, AMT +0.9%, EQC +0.8%, SHPG +0.8%
Other news:
- IMMP +5.8% (receives IND approval for eftilagimod alpha from FDA)
- PGNX +3.4% (FDA approved Azedra -- first treatment for rare adrenal tumors)
- QCOM +3% (commences modified Dutch auction tender offer to purchase up to $10 bln of shares of its common stock)
- CMI +2.8% (following ALSN results)
- NVCR +2.8% (publishes results from INNOVATE phase 2 pilot trial in Gynecologic Oncology)
Analyst comments:
- LEA +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TWTR +1.1% (upgraded to Neutral from Reduce at Nomura)